Sudan to start vaccine rollout next week after getting COVAX doses

PUBLISHED: Thu, 04 Mar 2021 13:17:54 GMT

KHARTOUM, March 4 (Reuters) – Sudan will begin vaccinating health care workers followed by people aged 45 or older with chronic conditions for free next week after becoming the first country in the Middle East and North Africa to benefit from COVAX facility vaccines.

Sudan received 828,000 doses of the AstraZeneca-produced vaccine on Wednesday at Khartoum airport, a health ministry official said. The delivery follows that of 4.5 metric tonnes of syringes and disposal boxes through COVAX in late February.

Sudan says it expects to receive the remainder of a total 3.4 million doses through COVAX, a vaccine-sharing programme co-led by the World Health Organization, in the second quarter of this year.

It aims to cover 20% of its population of 44 million through COVAX by September, health ministry officials said.

“This is an essential part of our battle against coronavirus,” Health Minister Omer Elnageib said.

Sudan was also in initial discussions to produce the vaccine domestically, Elnageib added.

Sudan is a young country, with only about 4% of its population over the age of 65, according to U.N. statistics.

It has been suffering from a long economic crisis that has left it unable to import some basic medicines and its health care system suffered from decades of neglect and sanctions under former President Omar al-Bashir before his overthrow in 2019.

As of March 1, Sudan had officially recorded 28,545 cases of coronavirus since the start of the pandemic one year ago, including 1,895 deaths. (Reporting by Khaild Abdelaziz and Nafisa Eltahir; Editing by Toby Chopra)

(c) Copyright Thomson Reuters 2021. Click For Restrictions –

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.